Adjuvant Chemotherapy in Head and Neck Cancer
Author Information
Author(s): P.M. Stell, N.S.B. Rawson
Primary Institution: University of Liverpool and Institute of Cancer Research
Hypothesis
Does adjuvant chemotherapy improve survival in patients with squamous cell carcinoma of the head and neck?
Conclusion
Adjuvant chemotherapy does not significantly improve survival rates in head and neck cancer patients compared to conventional treatments.
Supporting Evidence
- Meta-analysis showed an insignificant overall improvement in cancer mortality of 0.5%.
- Induction chemotherapy, synchronous chemotherapy, and induction/maintenance chemotherapy did not affect cancer mortality.
- Synchronous/maintenance therapy significantly reduced deaths from cancer.
Takeaway
Doctors tried using extra medicine to help people with throat and mouth cancer, but it didn't really help them live longer.
Methodology
A review of 23 randomized controlled trials analyzing survival, response rates, and toxicity of adjuvant chemotherapy.
Potential Biases
Publication bias and exclusion of patients before randomization may skew results.
Limitations
Many trials were too small to detect significant survival benefits, and a large number of eligible patients were excluded from analysis.
Participant Demographics
Patients with squamous cell carcinoma of the head and neck.
Statistical Information
P-Value
0.5%
Confidence Interval
0.89-1.17
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website